Table 2 Summary of previously published gastroblastoma cases
From: Gastroblastoma mimics the embryonic mesenchyme of the foregut: a case report
Case | Author (publication year) | Age (year) | Sex | Specimen type | Locus | Size (mm) | Chief complication | IHC positive | IHC negative | Fusion gene | Treatment | Metastases | Outcome | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1-3 | Miettinen et al. (2009) [1] | 19, 27, 30 | M, F, M | R | B, B, A | 50, 60. 150 | N/A, AP, anemia and fatigue | Vim (S), CD10 (S); CK (pan) (E); CK 18 (2/2, focally in one of the cases) (E); CK 7 (focally in E); DOG1 (focally in E, dot-like positivity in S) | CK20 (E); EMA (E); KIT (CD117) (E, S); CD34 (E, S); CD99 (E, S); SMA (E, S); Des (E, S); calretinin (E, S); p63 (E, S); S100 (E, S); CgA (E, S); Syn (E, S); CDX2 (E, S); and TTF-1 (E, S) | ND | SG, PG, antrectomy and radiation | No | ANED | 42, 60, 168 |
4 | Shin et al. (2010) [2] | 9 | M | R | A | 90 | AP and palpable mass. | CD10 (S); CD56; KIT (CD117) (E); CK (pan) (E); CK (LMW) (E); EMA (E); Vim (S) | Calretinin; CD34; CEA; CgA; CK (HMW); Des; inhibin; NSE; p63; SMA; Syn | ND | R | No | ANED | 9 |
5 | Wey et al. (2012) [3] | 28 | M | R | A | 38 | N/A | CD10; CD56; KIT (CD117) (E); CK (pan) (E); CK (LMW) (E); CK7 (focally in E); Vim (S) | CK20 (E); calretinin (E); CDX2 (E); Des (E); EMA (E); inhibin; p63 (E); S100 (E); SMA | ND | CHT followed by PG | LN, liver, | ANED | 3 |
6 | Femandes et al. (2014) [4] | 19 | F | R | A | 105 | AP | CD10 (S, focally in E); CD56; CK AE1/AE3 (E); CK CAM5.2 (E), Vim (S) | Calretinin; CD34; KIT (CD117); CgA; Des; DOG1; S100; SMA; Syn | ND | PG | No | ANED | 20 |
7 | Ma et al. (2014) [5] | 12 | M | R | A | 45 | Abdominal mass and blood in stool | CD10 (S); CD56 (S); CK AE1/AE3 (E); CK CAM5.2 (E); Vim (S) | ALK; CD34; KIT (CD117); CK5/6; Des; DOG1; PLAP; S100; SMA | ND | SG and gastroduodenostomy | No | ANED | 8 |
8 | Toumi et al. (2017) [10] | 29 | F | R | U | 70 | Epigastric pain | CD10 (focally); CD99 | CK (pan); KIT (CD117); CgA; Syn | ND | R | LN | DEAD | 6 |
9 | Graham et al. (2017) [6] | 28 | M | R | A | 38 | N/A | CK (pan) (E), CD56 (E), NSE (E), low Ki-67 | CgA, Syn, CEA, TTF-1, PLAP, CD30, AFP, HCG | MALAT1– GLI1 | R NOS | LN, liver, peritoneum | N/A | N/A |
10 | Graham et al. (2017 [6]) | 27 | M | R | A | ND | N/A | CK (pan) (E), SMA (patchy in S) | CgA, Syn, KIT (CD117), DOG1, Des, S100, melanA, SOX10, TLE-1, CD99, CK5/6 | MALAT1– GLI1 | R NOS | No | ANED | 12 |
11 | Graham et al. (2017) [6] | 9 | M | R | A | 90 | N/A | CK (pan) (E), CD10 (focally in S), KIT (CD117) (E, S), CD56 (E), Vim (S) | CgA, Syn, NSE, Des, SMA, calretinin, inhibin, CK34βE12, CD34 | MALAT1– GLI1 | R NOS | No | ANED | 93 |
12 | Graham et al. (2017) [6] | 56 | F | Needle biopsy | NS | 40 | N/A | OSCAR (patchy in E), low Ki-67, Vim (S) | CK34βE12, CKT7, CK20, CDX2, CgA, Syn, CD34, CD99, KIT (CD117), DOG1, calretinin, WT1, SMA, Des, EMA, MOC31, melanA, HMB45, pCEA | MALAT1– GLI1 | Biopsy | Liver | N/A | N/A |
13 | Castri et al. (2019) [7] | 79 | M | R | A | 90 | Weight loss and dysphagia | bcl2; CD10 (S> E); CD56; CK (pan) (E> S); Vim (S) | aFP, bHCG, h-caldesmon, calponin, CD31, CD99, KIT (CD117), CgA, Des, DOG1, ERG, GFAP, HMB45, melanA, PLAP, S100, STAT6, Syn | MALAT1– GLI1 | PG | Local relapse | ANED | 52 |
14 | Giovanni et al. (2019) | 43 | F | R | A | 53 | Intestinal bleeding | CD10 (focally in S), EMA (focally in E), CK (pan) (E), CAM 5.2 (E), CK 7 (focally in E), Vim (S), GLI1 (E, S) | SMA (E, S), Calretinin (E, S), CgA (E, S), NSE (E, S), CD34 (E, S), CD56 (E, S), CD99 (E, S), CDX2 (E, S), Des (E, S), DOG1 (E, S), ER (E, S), CK 5/6 (E), CK 20 (E, S), Inhibin (E, S), KIT (CD117) (E, S), p63 (E, S), Syn (E, S), S100 (E, S), TTF1 (E, S), TLE1 (E, S) | ND | PG | No | ANED | 100 |
15 | Koo et al. (2021) [8] | 17 | M | R | U | 63 | Intestinal bleeding | Vim (E, S), CD56 (E, S), CD10 (E, S), CK (pan) (E, S), Syn (E, S) | CD34 (E, S), KIT (CD117) (E, S), DOG1 (E, S), S100 (E, S), Des (E, S), CgA (E, S) | EWSR1-CTBP1 | PG | No | ANED | 23 |
16 | Chen C et al. (2022) [11] | 58 | M | R | M | 23 | N/A | Vim (E, S), CD10 (E, S), bcl-2 (E, S), CD56 (E), CD100 (E), EMA (focal), Ki-67 (low) | KIT (CD117) (E, S), DOG1 (E, S), CD34 (E, S), SMA (E, S), Des (E, S), SOX10 (E, S), CD99 (E, S), CgA (E, S), syn (E, S), CAM5.2 (E, S), CK (pan) (E, S). | PTCH-GLI2 | ESD | No | N/A | N/A |
17 | Present case / Sugimoto | 28 | F | R | A | 70 | AP | CK (pan) (E), CAM5.2 (E), CD10 (S), CD56 (S), Vim (S), GLI1 (S), CK 7 (E), PD-L1 (focally in S), HDAC2 (E, S) | CK20 (E, S), EMA (E, S), CDX2 (E, S), KIT (CD117) (E, S), CD34 (E, S), SMA (E, S), Des (E, S), S100 protein (E, S), CgA (E, S), Syn (E, S), DOG1 (E, S), SS18-SSX (E, S). | MALAT1– GLI1 | PG | No | ANED | 8 |